Skip to main content
. 2016 Feb 22;7(3):165–177. doi: 10.1007/s12672-016-0256-3

Table 4.

Summary of five large studies that reported associations between TERT promoter mutations and clinicopathological features of PTC

Muzza et al. 2015 [30] Xing M et al. 2014 [33] Liu X et al. 2014 [35] Melo M et al. 2014 [36] Liu T et al. 2014 [37] De Biase et al. 2015 [38]
M (22) W (160) P value M (61) W (446) P value M (42) W (325) P value M (25) W (307) P value M (18) W (38) P value M (19) W (385) P value
Age 57.6 (29–82) 44.2 (14–80) 0.004 51.7 ± 15.7 45.1 ± 13.6 <0.001 53.40 ± 16.14 43.66 ± 12.91 0.00 58.4 ± 13.2 43.6 ± 15.3 <0.001 68 (49–84) 36 (22–97) <0.0001 50.2 ± 11.5 47.8 ± 12.8 0.39
Size 2.2 1.93 0.34 2.3 (1.2–3.5) 1.8 (1.1–3) 0.048 3.14 ± 1.62 2.48 ± 1.58 0.03 3.2 ± 2.2 2.3 ± 1.4 0.005 5.9 ± 2.9 6.2 ± 2.5 0.68
ETE 11/22 (50) 85/160 (53.1) 0.9 27/58 (46.5) 66/439 (15) <0.001 9/32 (28.1) 17/207 (8.2) 0.00 14/18 (77.8) 162/250 (64.8)) 0.26
Vascular invasion 14/54 (25.9) 63/437 (14.1) 0.028 5/16 (31.3) 98/241 (40.7) 0.46
LNM 11/22 (50) 83/160 (51.8) 0.9 31/59 (50.8) 122/438 (27.8) <0.001 7/26 (26.9) 68/213 (31.9) 0.60 18/23 (6) 184/275 (66.9) 0.26 4/12 (33.3) 53/254 (20.8) 0.29
Distant Mets 12/61 (19.7) 10/446 (2.2) <0.001 5/18 (27.8) 31/275 (14.7) 0.07 7/13 (53.8) 3/38 (7.9) 0.001
Higher TNM III/IV 10/22 (45.5) 49/160 (30.6) 0.09 29/61 (47.5) 77/446 (17.5) <0.001 11/26 (42.31) 52/213 (24.41) 0.05 10/14 (71.4) 66/211 (31.3) 0.02 4/15 (26.7) 61/332 (18.4) 0.62
Recurrence 10/22 (45) 29/160 (18) 0.002 29/61 (47.5) 51/466 (11.4) <0.001 10/16 (62.5) 48/195 (24.6) 0.001 1/12 (8.3) 6/276 (2.2) 0.20
BRAF V600E 10/64 (15.6) 54/160 (33.8) 0.34 35/61 (57.8) 159/446 (35.750 0.007 40/46 (86.9) 210/362 (58) <0.001 18/24 (75) 130/277 (46.9) 0.008
Death 2/19 (10.5) 3/256 (1.1) 0.001 11/13 (84.6) 8/38 (21.1) <0.0001

ETE extrathyroidal extension/invasion, LNM lymph node metastases, Mets metastases, TNM tumor node metastasis staging system